Genmab A/S (GMAB)
| Market Cap | 18.52B |
| Revenue (ttm) | 2.44B |
| Net Income (ttm) | 644.74M |
| Shares Out | 653.79M |
| EPS (ttm) | 0.94 |
| PE Ratio | 30.35 |
| Forward PE | 26.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 242,410 |
| Open | 28.46 |
| Previous Close | 28.53 |
| Day's Range | 28.29 - 28.62 |
| 52-Week Range | 26.32 - 42.72 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 45.20 (+59.55%) |
| Earnings Date | May 8, 2024 |
About GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB... [Read more]
Financial Performance
In 2022, Genmab's revenue was 14.51 billion, an increase of 72.33% compared to the previous year's 8.42 billion. Earnings were 5.45 billion, an increase of 84.38%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for GMAB stock is "Strong Buy." The 12-month stock price forecast is $45.2, which is an increase of 59.55% from the latest price.
News
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
Company Announcement Net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Den...
Transactions in Connection with Share Buy-back Program Genmab
Company Announcement COPENHAGEN, Denmark; April 15, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; April 8, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion ...
Biotech giant Genmab to acquire Seattle company ProfoundBio in $1.8B deal
ProfoundBio, a Seattle-based biotech firm developing drugs to treat ovarian and endometrial cancers, will be acquired by publicly traded Danish drugmaker Genmab in a $1.
Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio
Danish drugmaker Genmab A/S (GMAB) said Wednesday that it is buying privately held U.S. biotech firm ProfoundBio Inc. for $1.8 billion in cash as it expands its pipeline of cancer treatments.
Denmark's Genmab to acquire ProfoundBio for $1.8 billion
Danish biotech Genmab has agreed to buy U.S. cancer drug maker ProfoundBio for $1.8 billion, the two companies said on Wednesday.
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
COPENHAGEN, Denmark & SEATTLE--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. announced today that the companies have entered into a definitive agreement for Genmab to acquire Profou...
Completion of share buy-back program
Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announc...
Genmab Announces Initiation of Share Buy-Back Program
Company Announcement Repurchase of up to DKK 3.5 billion worth of shares Completion expected no later than December 16, 2024 COPENHAGEN, Denmark; March 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced t...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; March 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, th...
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; March 13, 2024 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 13, 2024, the Company's Board of Directors met to consti...
Passing of Genmab A/S' Annual General Meeting
Company Announcement At Genmab A/S' Annual General Meeting held today March 13, 2024, the Annual Report for 2023 was approved Discharge was given to the Board of Directors and the Executive Management...
Transactions in connection with share buy-back program
Company Announcement COPENHAGEN, Denmark; March 11, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under o...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The incr...
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) granted Priority Review for the supplemental Biologi...
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; February 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and empl...
Notice to Convene the Annual General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 13, 2024 COPENHAGEN, Denmark; February 15, 2024 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wedn...
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Media Release COPENHAGEN, Denmark; February 14, 2024 Genmab filed Form 20-F for the financial year 2023 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report ...
Genmab Publishes 2023 Annual Report
Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, ...
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for review the marketing authorizatio...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; January 25, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,281 restricted stock units and 5,468 warrants to employees of t...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023
Company Announcement Net sales of DARZALEX® in 2023 totaled USD 9,744 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 23, 202...
Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
Company Announcement COPENHAGEN, Denmark; January 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the appeal arbitrator in its second arbitration arising under its license agreement with Jan...
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
NEW YORK & COPENHAGEN, Denmark--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Bi...
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics Li...